SB/Incyte molecular diagnostics venture targeting infectious disease, oncology test development.
This article was originally published in The Gray Sheet
Executive Summary
DIADEXUS' HOME BREW REAGENTS TO ENTER CLINICAL USE IN NEXT 1-3 YEARS, SmithKline Beecham estimates. SmithKline and Incyte Pharmaceuticals announced Sept. 2 formation of joint venture diaDexus to pursue development of molecular in vitro diagnostics.